Valeant no Enron; Stock Market Overreacting says David Kass

Valeant no Enron; Stock Market Overreacting says David Kass

Valeant Pharmaceuticals’ stock dive, after short-selling research firm Citron called it “pharmaceutical Enron,” “is a gross overreaction in the market caused by charges thus far that are unsubstantiated and denied by Valeant,” says Clinical Professor of Finance David Kass at the University of Maryland’s Robert H. Smith School of Business.

“Valeant investors, including Jeff Ubben and Bill Ackman are extremely sophisticated and successful hedge fund managers,” says Kass a long-time observer of Valeant stock and former health economist for the Federal Trade Commission.

“It’s difficult to fathom these star investors allowing for, or being unaware of, Valeant manipulating a network of specialty mail-order pharmacies in order to inflate the sales of its high-priced drugs.”

Trident Fund LP February 2021 Performance Update

Trident Fund LP PerformanceTrident Fund LP performance update for the month ended February 2021. Q4 2020 hedge fund letters, conferences and more Trident Fund LP Performance The Trident Fund LP returned 6.1 percent in February, and the fund is -0.5  percent net for 2021. In February, Trident profited from rising interest rates and commodity prices to regain losses sustained Read More

“And unlike Enron, Valeant has real products through brands like Bausch & Lomb and popular pharmaceuticals.”

Nonetheless, “there’s confusion in the market,” Kass says, referring to Valeant stock opening Wednesday at $148 and dropping to $88 before climbing back to $120 in mid-afternoon as Valeant refuted Citron’s claim. “Today’s trading volume has been 10 times heavier than usual. Traders sense real problems with the stock, regardless of the validity of the allegations.”

Valeant was trading at $240 about a month ago. But its stock went in decline, says Kass, because CEO Michael Pearson – in bowing to regulator-scrutiny of its patient assistance programs, drug distribution and pricing decisions – announced the company would change its profitable business model of acquisitions, subsequent cost cutting and price increases. “This alone, negatively affects Valeant’s expected rate of growth,” he says.

Kass blogs at

Contact him at [email protected] and @DrDavidKass on Twitter

No posts to display